HCA Healthcare Is Maintained at Equal-Weight by Wells Fargo
HCA Healthcare Analyst Ratings
Wells Fargo Maintains HCA Healthcare(HCA.US) With Hold Rating, Raises Target Price to $400
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Exact Sciences (EXAS) and Crispr Therapeutics AG (CRSP)
Cantor Fitzgerald Maintains HCA Healthcare(HCA.US) With Buy Rating, Raises Target Price to $405
HCA Healthcare Price Target Cut to $440.00/Share From $450.00 by TD Cowen
Leerink Partners Maintains HCA Healthcare(HCA.US) With Buy Rating, Raises Target Price to $460
Oppenheimer Maintains HCA Healthcare(HCA.US) With Buy Rating, Raises Target Price to $400
A Quick Look at Today's Ratings for HCA Healthcare(HCA.US), With a Forecast Between $396 to $460
HCA Healthcare Is Maintained at Outperform by Oppenheimer
HCA Healthcare Analyst Ratings
Leerink Partners Adjusts HCA Healthcare's Price Target to $460 From $465, Keeps Outperform Rating
HCA Healthcare (HCA) Gets a Buy From RBC Capital
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Viatris (VTRS) and Syndax Pharmaceuticals (SNDX)
Promising Outlook for HCA Healthcare: Strong Fundamentals and Strategic Management Support Buy Rating
Morgan Stanley Maintains HCA Healthcare(HCA.US) With Hold Rating, Maintains Target Price $427
Bernstein Keeps Their Hold Rating on HCA Healthcare (HCA)
HCA Healthcare: Hold Recommendation Amid Modest Misses and External Challenges
Mizuho Securities Maintains HCA Healthcare(HCA.US) With Buy Rating
HCA Healthcare's Strong Q3 2024 Performance Amid Challenges Reinforces Buy Rating
No Data
No Data